Successfully optimized the different regions:
• Small molecule inhibitor, novel IP generation
• Spacer: length and orientation
• Linker: length
• CRBN ligand
DOWNLOAD TO LEARN MORE>>>>
Literature / Brochures
Targeted Protein Degradation at Syngene
Syngene has extensive experience in PROTACs
DOWNLOAD TO LEARN MORE>>>>
More Literature / Brochures by Syngene
-
Brochures
-
Brochures
-
Brochures
-
Brochures
-
Brochures
-
Brochures
-
Brochures
More Content From Syngene
-
Your Pre-clinical Toxicology Program Needs a Strategy
By Mohan Krishnappa, DVM, Ph.D., DABT Lead Toxicologist Safety Assessment at SyngeneCase Studies Released on 01.14.2021
-
Outsourcing’s Answer to the Innovation and ROI Challenge in the Biopharmaceutical Industry
The Dedicated CenterCase Studies Released on 01.13.2021
-
Proactive COVID-19 Testing: The Next Step in Learning to Live with the Pandemic
...Case Studies Released on 01.12.2021
-
How Integrated CMC Can Help Expedite Early Phase Development of Small Molecules – A CRO Perspective
By Badrinath Doniparthi, Group Leader – CMC at SyngeneCase Studies Released on 01.11.2021
-
Harnessing Targeted Protein Degradation
Driving programs to candidate delivery stage for a leading biotechCase Studies Released on 01.08.2021
-
THE MANY BENEFITS OF OUTSOURCING STABILITY: A BAXTER-SYNGENE CASE STUDY
...Case Studies Released on 01.07.2021
-
Syngene and Deerfield Discovery and Development (3DC) sign 5-year strategic collaboration
...News Releases Released on 11.19.2020
-
Syngene eases clients’ path to drug discovery
Anil Urs - BengaluruNews Releases Released on 10.30.2020
-
Syngene International Q2 profit up 64 pc to Rs 128 cr
Press Trust of India | New DelhiNews Releases Released on 10.22.2020
-
Syngene joins global consortium to accelerate research in COVID-19 testing
The consortium brings together a diverse group of companies with synergistic areas of expertiseNews Releases Released on 10.02.2020
